- Previous Close
61.07 - Open
61.51 - Bid 60.18 x 800
- Ask 60.26 x 800
- Day's Range
59.62 - 62.11 - 52 Week Range
59.62 - 170.47 - Volume
6,187,340 - Avg. Volume
4,671,087 - Market Cap (intraday)
23.141B - Beta (5Y Monthly) 1.66
- PE Ratio (TTM)
-- - EPS (TTM)
-15.35 - Earnings Date Oct 31, 2024 - Nov 4, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
101.94
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; rare disease intracellular therapeutics; and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck & Co., Inc; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; The Bill & Melinda Gates Foundation; and OpenAI. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
www.modernatx.comRecent News: MRNA
View MorePerformance Overview: MRNA
Trailing total returns as of 10/4/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: MRNA
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: MRNA
View MoreValuation Measures
Market Cap
23.14B
Enterprise Value
15.92B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
4.61
Price/Book (mrq)
1.98
Enterprise Value/Revenue
3.19
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-116.18%
Return on Assets (ttm)
-15.42%
Return on Equity (ttm)
-40.94%
Revenue (ttm)
5.05B
Net Income Avi to Common (ttm)
-5.87B
Diluted EPS (ttm)
-15.35
Balance Sheet and Cash Flow
Total Cash (mrq)
8.49B
Total Debt/Equity (mrq)
10.84%
Levered Free Cash Flow (ttm)
-2.35B
Research Analysis: MRNA
View MoreCompany Insights: MRNA
MRNA does not have Company Insights
Research Reports: MRNA
View MoreArgus Quick Note: Weekly Stock List for 09/30/2024: Shooting Stars and Falling Angels in 3Q24
The third quarter of 2024 has been rewarding for equity investors, as the S&P 500 increased another 5% and has gained almost 20% year to date. Surprise, surprise, though, as value was the segment leader in the quarter. The S&P 500 Value Index advanced approximately 7% in the period, while the S&P 500 Growth Index edged only 3% higher. Leading sectors included Real Estate, Utilities, Financial, Healthcare and Industrials, while lagging sectors for the past three months included Information Technology and Energy. The average stock in the Argus Universe of Coverage rose almost 8% during the quarter, while the median stock increased 9%. The average BUY-rated stock rose 8.3%, while the average HOLD-rated stock gained 6.7%. Here are the top-10 and bottom-five performers from the Argus Universe in 3Q24.
Moderna: R&D Day Brings Dramatic Strategic Shift; Lowering Our Fair Value Estimate by 38%
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
RatingPrice TargetMid Cap U.S. Pick List September 2024
This pick list highlights constituents of the Morningstar US Mid Cap Index that we believe offer investors the best risk-adjusted return prospects. The market capitalization range for U.S. mid-caps typically falls between $1 billion and $8 billion and represents 20% of the total capitalization of the U.S. equity market.
Discounted price offers buying opportunity
Moderna Inc., a clinical stage biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious and cardiovascular diseases, rare diseases, immunological conditions, and cancer. The company has approximately 5,150 employees.
RatingPrice Target
Top Analysts: MRNA
View MoreOverall Score
Discover which analysts rank highest for MRNA overall weighted by direction, price target, and price movement.
Learn MoreDirection Score
Discover which analysts rank highest on predicting the directional movement of MRNA.
Learn MorePrice Score
Discover which analysts rank highest on predicting the price target of MRNA.
Learn More